Co-administration of Aripiprazole and Lumateperone: Safety and Efficacy Considerations

Introduction to Antipsychotic Polypharmacy

• The American College of Cardiology and other guideline societies recommend antipsychotic monotherapy as the standard of care for patients with schizophrenia, due to the increased risk of side effects with polypharmacy 1, 3
• Antipsychotic polypharmacy is generally not recommended, except in specific cases of treatment-resistant schizophrenia, typically after clozapine failure, as advised by the National Institute for Health and Care Excellence (NICE) 3, 6

Safety Considerations

• Co-administration of multiple antipsychotics increases the global side-effect burden, including risk of Parkinsonian side effects, anticholinergic effects, hyperprolactinemia, sexual dysfunction, sedation, and cognitive impairment, with a strength of evidence level of high 1
• The combination of aripiprazole and lumateperone may increase the risk of QT interval prolongation, as both medications individually can affect cardiac conduction, based on moderate evidence 4
• Drug-drug interactions are a significant concern when combining antipsychotics, especially those affecting the same metabolic pathways, with a strength of evidence level of moderate 5

Clinical Guidelines on Antipsychotic Polypharmacy

• The National Institute for Health and Care Excellence (NICE) guidelines advise against regular combined antipsychotic medication except for short periods, with a strength of evidence level of high 3
• Guidelines only consider antipsychotic polypharmacy in specific cases of treatment-resistant schizophrenia, typically after clozapine failure, based on high-level evidence 6
• When polypharmacy is considered, it is generally recommended to select antipsychotics with differing side-effect profiles to minimize additive adverse effects, with a strength of evidence level of moderate 1

Alternative Approaches

• If a patient is not responding adequately to one antipsychotic, the recommended approach is to try a different antipsychotic as monotherapy before considering polypharmacy, based on high-level evidence 6
• For treatment-resistant cases, clozapine should be considered before antipsychotic combinations, with a strength of evidence level of high 1, 6

Monitoring if Co-administration is Attempted

• If co-administration is deemed clinically necessary despite the risks, close monitoring is essential for cardiac effects, extrapyramidal symptoms, metabolic parameters, sedation, and cognitive effects, with a strength of evidence level of moderate 1, 4, 6